Novo Nordisk CEO Mike Doustdar Talks Drug Sales
Bloomberg Talks
00:00
Concerns Over Compounded Copycat Drugs
Guy asks about compounding loopholes; Doustdar criticizes unsafe use of unapproved APIs in injectables and says Novo will lobby to close those practices.
Play episode from 06:17
Transcript
